275,313 Shares in Insulet Corporation $PODD Bought by Jupiter Topco LLC

Key Points

• Jupiter Topco LLC acquired 275,313 Insulet shares in the second quarter, worth approximately $41.9 million and representing about 0.40% of the company.
• Analyst sentiment is mixed but cautious: several firms sharply cut price targets, while Insulet has an average “Hold” rating and a consensus target of $195.40.
• Insulet exceeded quarterly expectations with $1.66 in EPS and $801.7 million in revenue, up 23.5% year over year, but faces potential legal and reputational risks from a securities-fraud lawsuit alleging manufacturing and quality-control disclosures were inadequate.

Jupiter Topco LLC acquired a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 275,313 shares of the medical instruments supplier's stock, valued at approximately $41,917,000. Jupiter Topco LLC owned about 0.40% of Insulet at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet during the fourth quarter valued at about $26,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the fourth quarter valued at about $28,000. DV Equities LLC bought a new stake in shares of Insulet in the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet in the 4th quarter valued at about $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Analysts Set New Price Targets

PODD has been the subject of several recent analyst reports. Leerink Partners lowered shares of Insulet from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $247.00 to $145.00 in a research note on Thursday, August 6th. TD Cowen lowered their target price on shares of Insulet from $294.00 to $144.00 and set a "hold" rating for the company in a research note on Thursday, August 6th. Sanford C. Bernstein lowered their target price on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Raymond James Financial reaffirmed an "outperform" rating and issued a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. Finally, Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $195.40.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company's stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by company insiders.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $143.41 on Friday. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.95 billion, a PE ratio of 26.81, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company's 50 day moving average is $154.47 and its 200 day moving average is $181.40.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business's quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts forecast that Insulet Corporation will post 6.51 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.